Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Experimental Hematology

Volumn 36, Issue 5, 2008, Pages 535-544

  Michallet, Mauricette ^a   Le, Quoc Hung ^a   Mohty, Mohamad ^b   Prébet, Thomas ^a   Nicolini, Franck ^a   Boiron, Jean Michel ^c   Esperou, Hélène ^d   Attal, Michel ^e   Milpied, Noel ^b   Lioure, Bruno ^f   Bordigoni, Pierre ^g   Yakoub Agha, Ibrahim ^h   Bourhis, Jean Henri ⁱ   Rio, Bernard ^j   Deconinck, Eric ^k   Renaud, Marc ^l   Chir, Zina ^m   Blaise, Didier ⁿ  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c Hôpital Pessac   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CHU PURPAN   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g Hôpital Nancy   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j HÔTEL DIEU   (France)

^k Hôpital de Besançon   (France)

^l Gastroenterology Department   (France)

^m Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM TC)   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ORYCTOLAGUS CUNICULUS;

EID: 42249099016     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.01.017     Document Type: Article

References (44)

1. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
2. Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 993;270:57-60.
3. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., and Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304 (1981) 1529-1533
4. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068-1073
5. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
6. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
7. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
8. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
9. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (1999) 1755-1759
10. Carella A.M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 18 (2000) 3918-3924
11. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
12. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
13. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
14. Michallet M., Bilger K., Garban F., et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19 (2001) 3340-3349
15. Martino R., Caballero M.D., Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
16. Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102 (2003) 470-476
17. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
18. Gail M. A review and critique of some models used in competing risk analysis. Biometrics 31 (1975) 209-222
19. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35 (1977) 1-39
20. Martino R., Perez-Simon J.A., Moreno E., et al. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant 11 (2005) 437-447
21. Barrett J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Curr Opin Immunol 18 (2006) 592-598
22. Nagler A., Aker M., Or R., et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 29 (2001) 362-370
23. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21 (2007) 1387-1394
24. Nakai K., Mineishi S., Kami M., et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 75 (2003) 2135-2143
25. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 12 (2005) 457-462
26. Alessandrino E.P., Bernasconi P., Colombo A.A., et al. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplant 34 (2004) 1039-1045
27. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 33 (2004) 691-696
28. Farag S.S., Elder P.J., Marcucci G., et al. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged > or = 50 years compared to younger adults with low-risk disease. Bone Marrow Transplant 31 (2003) 87-93
29. Slavin S. Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. Transplantation 78 (2004) 964-965
30. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
31. Le Blanc K., Remberger M., Uzunel M., Mattsson J., Barkholt L., and Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 78 (2004) 1014-1020
32. Valcarcel D., Martino R., Sureda A., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 74 (2005) 144-151
33. Blaise D., Vey N., Faucher C., and Mohty M. Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92 (2007) 533-541
34. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
35. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17 (2003) 841-848
36. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 (2003) 2747-2753
37. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176
38. Sureda A., and Schmitz N. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Ann Hematol 82 (2003) 1-13
39. Atkinson K., Horowitz M.M., Gale R.P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75 (1990) 2459-2464
40. Brown R.A., Adkins D., Khoury H., et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 17 (1999) 806-812
41. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 102 (2003) 1108-1113
42. Mohty M., Bagattini S., Chabannon C., et al. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 32 (2004) 1097-1102
43. Worel N., Kalhs P., Keil F., et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 43 (2003) 1153-1161
44. Seebach J.D., Stussi G., Passweg J.R., et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 11 (2005) 1006-1013